New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:07 EDTCNCE, CELG, JAZZConcert Pharmaceuticals reports FY13 EPS ($4.99) vs. (16.15) last year
Concert Pharmaceuticals reports FY13 revenue $25.4M vs. $12.8M last year. The company said, "The increase in revenue was primarily due to license and research and development revenue of $17M and $3.7M recognized for the year ended December 31, 2013 in connection with collaborations entered into with Celgene (CELG) and Jazz Pharmaceuticals (JAZZ) respectively, during 2013."
News For CNCE;CELG;JAZZ From The Last 14 Days
Check below for free stories on CNCE;CELG;JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:00 EDTCELG, CNCEConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 15, 2014
07:27 EDTCELGIBC Life Sciences to hold a conference
Subscribe for More Information
September 12, 2014
16:12 EDTCNCEBiotechnology Value Fund reports 6.7% passive stake in Concert Pharmaceuticals
September 9, 2014
07:51 EDTCELGNICE says Abraxane price not justified by limited benefit in pancreatic cancer
Subscribe for More Information
September 8, 2014
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:26 EDTCELGMorgan Stanley to hold a conference
Subscribe for More Information
07:21 EDTJAZZJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use